Anti-cytokine therapy in systemic lupus erythematosus

In the course of the disease, a wide variety of cytokines is dysregulated, many of which likely influence systemic lupus erythematosus (SLE) autoimmunity and/or lupus tissue inflammation. Proinflammatory cytokines in particular, such as TNF, IL-6, IL-18 or IFN-gamma, may play a major role in propagating the inflammatory processes responsible for tissue damage. These cytokines are overexpressed both systemically and locally, and preliminary results from open-label trials and/or animal studies suggest potential benefits of blocking either of these inflammatory mediators. Since new therapeutic agents may soon offer many ways to influence the process, controlled clinical trials following open-label safety studies are of central importance to arrive at optimized therapies for SLE patients.

[1]  M. Aringer,et al.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. , 2004, Arthritis and rheumatism.

[2]  M. Aringer,et al.  Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention , 2004, Lupus.

[3]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[4]  P. Hawkins,et al.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. , 2003, The New England journal of medicine.

[5]  M. Aringer,et al.  SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus , 2003, Arthritis research & therapy.

[6]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[7]  M. Aringer,et al.  Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death , 2002, Lupus.

[8]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[9]  G-H Sun,et al.  Monoclonal anti‐double‐stranded DNA autoantibody stimulates the expression and release of IL‐1β, IL‐6, IL‐8, IL‐10 and TNF‐α from normal human mononuclear cells involving in the lupus pathogenesis , 2000, Immunology.

[10]  S. Nakae,et al.  Development of Chronic Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Interleukin 1 Receptor Antagonist–Deficient Mice , 2000, The Journal of experimental medicine.

[11]  A. Theofilopoulos,et al.  Tumour necrosis factor and other cytokines in murine lupus , 1999, Annals of the rheumatic diseases.

[12]  F. Houssiau,et al.  Cytokines: clues to the pathogenesis of SLE , 1998, Lupus.

[13]  J. Ravetch,et al.  Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. , 1998, Science.

[14]  J. Harley,et al.  An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. , 1997, The Journal of clinical investigation.

[15]  J. Smolen,et al.  Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. , 1996, British journal of rheumatology.

[16]  B. Kiberd,et al.  Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? , 1995, Immunopharmacology.

[17]  D. Malide,et al.  Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. , 1995, Human pathology.

[18]  D. Wofsy,et al.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. , 1994, The Journal of clinical investigation.

[19]  B. Ryffel,et al.  Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. , 1994, The American journal of pathology.

[20]  D. Brennan,et al.  Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. , 1989, Journal of immunology.

[21]  J. M. Boswell,et al.  Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. , 1988, Journal of immunology.

[22]  W. Buurman,et al.  Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. , 1988, Journal of immunology.

[23]  H. Bergmeister,et al.  Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. , 2004, Arthritis and rheumatism.

[24]  P. Tugwell,et al.  Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. , 2000, Lupus.

[25]  V. Holers.  Complement receptors. , 1989, The Year in immunology.